Glenmark Pharmaceuticals has reported a robust 15.8% year-on-year increase in its consolidated revenue for the fourth quarter of fiscal year 2025-26, reaching Rs 3,770.6 crore. This growth was driven by strong performance across its key markets, including the United States, Europe, and emerging markets.
Financial Highlights
The company's revenue for the quarter ended March 31, 2026, stood at Rs 3,770.6 crore, compared to Rs 3,256.2 crore in the same period last year. The growth was primarily attributed to higher sales in the generics and specialty segments. Glenmark's net profit for the quarter also saw a significant uptick, rising by 22.3% to Rs 456.8 crore from Rs 373.5 crore in Q4 FY25.
Segment-Wise Performance
The company's formulation business in the United States grew by 18.2% year-on-year, driven by new product launches and market share gains. In Europe, revenue increased by 12.5%, supported by strong demand for its dermatology and respiratory products. Emerging markets, including Asia and Africa, contributed a 14.3% growth, led by India and South Africa.
Strategic Initiatives
During the quarter, Glenmark continued to focus on expanding its pipeline of complex generics and specialty drugs. The company received approval for three new Abbreviated New Drug Applications (ANDAs) from the US Food and Drug Administration (FDA), further strengthening its product portfolio. Additionally, Glenmark invested in research and development, with R&D spend increasing to 8.5% of revenue from 7.9% in the previous year.
Management Commentary
Commenting on the results, Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals, said, "We are pleased with our performance this quarter, which reflects the strength of our diverse portfolio and our ability to execute in a dynamic market environment. Our focus on innovation and operational efficiency continues to drive growth and create value for our stakeholders."
Outlook
Looking ahead, Glenmark expects to maintain its growth trajectory, driven by new product launches and expansion in key markets. The company aims to file 10-12 ANDAs in the next fiscal year and plans to launch several specialty products in the US and Europe. Glenmark also remains committed to its sustainability goals, with initiatives to reduce carbon emissions and enhance energy efficiency across its manufacturing sites.
Overall, Glenmark Pharmaceuticals' strong Q4 performance underscores its resilience and strategic focus, positioning it well for future growth in the competitive pharmaceutical landscape.
